EBS logo

Emergent BioSolutions (EBS) Cash From Investing

Annual CFI

$125.20 M
-$87.10 M-41.03%

December 31, 2024

Summary

Performance

1-Year Change

-41.03%

3-Year Change

+155.87%

5-Year Change

+229.21%

15-Year Change

+150.1%

EBS Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

94.98%
EBS annual cash flow from investing activities is higher than 94.98% of companies in Healthcare sector

High & Low

All-time High

$212.30 M
EBS annual cash flow from investing activities is currently -41.03% below its historical high of $212.30 million

3-Year Low

-$381.30 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
EBS previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
EBS next annual earnings announcement has not yet been scheduled

OtherEBScash flowmetrics:

Annual CFF

-$190.00 M
EBS annual cash flow from financing activities is -$190.00 million

Annual CFO

$58.70 M
EBS annual cash flow from operations is $58.70 million

Annual FCF

$35.80 M
EBS annual free cash flow is $35.80 million

Annual CAPEX

$22.90 M
EBS annual capital expenditures is $22.90 million

Quarterly CFI

$28.60 M
-$83.40 M-74.46%

December 31, 2024

Summary

Performance

3-Month Change

-74.46%

1-Year Change

-74.46%

3-Year Change

+162.45%

5-Year Change

+150.98%

EBS Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

91.14%
EBS quarterly cash flow from investing activities is higher than 91.14% of companies in Healthcare sector

High & Low

All-time High

$257.70 M
EBS quarterly cash flow from investing activities is currently -88.90% below its historical high of $257.70 million

3-Year Low

-$271.60 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
EBS previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 1, 2025
EBS next earnings announcement is scheduled for May 1, 2025

OtherEBScash flowmetrics:

Quarterly CFF

$500.00 K
EBS quarterly cash flow from financing activities is $500.00 thousand

Quarterly CFO

-$79.90 M
EBS quarterly cash flow from operations is -$79.90 million

Quarterly FCF

-$81.60 M
EBS quarterly free cash flow is -$81.60 million

Quarterly CAPEX

$1.70 M
EBS quarterly capital expenditures is $1.70 million

TTM CFI

$125.20 M
+$40.00 M+46.95%

December 31, 2024

Summary

Performance

3-Month Change

+46.95%

1-Year Change

+46.95%

3-Year Change

+155.87%

5-Year Change

+168.12%

EBS TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

95.48%
EBS TTM cash flow from investing activities is higher than 95.48% of companies in Healthcare sector

High & Low

All-time High

$216.60 M
EBS TTM cash flow from investing activities is currently -42.20% below its historical high of $216.60 million

3-Year Low

-$381.70 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
EBS previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 1, 2025
EBS next earnings announcement is scheduled for May 1, 2025

OtherEBScash flowmetrics:

TTM CFF

-$190.00 M
EBS TTM cash flow from financing activities is -$190.00 million

TTM CFO

$58.70 M
EBS TTM cash flow from operations is $58.70 million

TTM FCF

$35.80 M
EBS TTM free cash flow is $35.80 million

TTM CAPEX

$22.90 M
EBS TTM capital expenditures is $22.90 million

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

EBS Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-41.0%-74.5%+47.0%
3 y3 years+155.9%+162.4%+155.9%
5 y5 years+229.2%+151.0%+168.1%

EBS Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-41.0%+132.8%-88.9%+110.5%-42.2%+132.8%
5 y5-year-41.0%+132.8%-88.9%+110.5%-42.2%+132.8%
alltimeall time-41.0%+114.0%-88.9%+103.4%-42.2%+113.6%

Emergent BioSolutions Cash From Investing History

DateAnnualQuarterlyTTM
Dec 2024
$125.20 M(-41.0%)
$28.60 M(-74.5%)
$125.20 M(+46.9%)
Sep 2024
-
$112.00 M(-2534.8%)
$85.20 M(-286.4%)
Jun 2024
-
-$4.60 M(-57.4%)
-$45.70 M(-121.1%)
Mar 2024
-
-$10.80 M(-5.3%)
$216.60 M(+2.0%)
Dec 2023
$212.30 M(-155.7%)
-$11.40 M(-39.7%)
$212.30 M(+19.1%)
Sep 2023
-
-$18.90 M(-107.3%)
$178.30 M(-339.7%)
Jun 2023
-
$257.70 M(-1806.6%)
-$74.40 M(-79.6%)
Mar 2023
-
-$15.10 M(-66.7%)
-$364.20 M(-4.5%)
Dec 2022
-$381.30 M(+70.1%)
-$45.40 M(-83.3%)
-$381.30 M(-0.1%)
Sep 2022
-
-$271.60 M(+746.1%)
-$381.70 M(+130.9%)
Jun 2022
-
-$32.10 M(-0.3%)
-$165.30 M(-17.4%)
Mar 2022
-
-$32.20 M(-29.7%)
-$200.20 M(-10.7%)
Dec 2021
-$224.10 M(+47.5%)
-$45.80 M(-17.0%)
-$224.10 M(+4.1%)
Sep 2021
-
-$55.20 M(-17.6%)
-$215.20 M(+4.6%)
Jun 2021
-
-$67.00 M(+19.4%)
-$205.70 M(+11.9%)
Mar 2021
-
-$56.10 M(+52.0%)
-$183.80 M(+21.0%)
Dec 2020
-$151.90 M(+56.8%)
-$36.90 M(-19.3%)
-$151.90 M(+0.5%)
Sep 2020
-
-$45.70 M(+1.3%)
-$151.10 M(+25.2%)
Jun 2020
-
-$45.10 M(+86.4%)
-$120.70 M(+21.1%)
Mar 2020
-
-$24.20 M(-33.0%)
-$99.70 M(+2.9%)
Dec 2019
-$96.90 M(-89.2%)
-$36.10 M(+135.9%)
-$96.90 M(-89.3%)
Sep 2019
-
-$15.30 M(-36.5%)
-$909.30 M(-1.2%)
Jun 2019
-
-$24.10 M(+12.6%)
-$920.10 M(+1.4%)
Mar 2019
-
-$21.40 M(-97.5%)
-$907.00 M(+1.1%)
Dec 2018
-$897.20 M(+259.0%)
-$848.50 M(+3151.0%)
-$897.20 M(+250.2%)
Sep 2018
-
-$26.10 M(+137.3%)
-$256.22 M(+5.5%)
Jun 2018
-
-$11.00 M(-5.2%)
-$242.90 M(+0.7%)
Mar 2018
-
-$11.60 M(-94.4%)
-$241.20 M(-3.5%)
Dec 2017
-$249.90 M(+228.0%)
-$207.52 M(+1524.3%)
-$249.90 M(+300.9%)
Sep 2017
-
-$12.78 M(+37.4%)
-$62.34 M(-6.3%)
Jun 2017
-
-$9.30 M(-54.2%)
-$66.56 M(-15.0%)
Mar 2017
-
-$20.30 M(+1.7%)
-$78.29 M(+2.7%)
Dec 2016
-$76.20 M(+67.6%)
-$19.96 M(+17.4%)
-$76.20 M(+11.9%)
Sep 2016
-
-$17.00 M(-19.2%)
-$68.07 M(+4.7%)
Jun 2016
-
-$21.03 M(+15.5%)
-$65.03 M(+19.1%)
Mar 2016
-
-$18.21 M(+54.0%)
-$54.59 M(+20.1%)
Dec 2015
-$45.46 M
-$11.83 M(-15.2%)
-$45.46 M(-10.7%)
DateAnnualQuarterlyTTM
Sep 2015
-
-$13.95 M(+31.6%)
-$50.90 M(+20.7%)
Jun 2015
-
-$10.60 M(+16.7%)
-$42.17 M(+15.9%)
Mar 2015
-
-$9.08 M(-47.4%)
-$36.38 M(-82.7%)
Dec 2014
-$210.05 M(+209.4%)
-$17.26 M(+230.7%)
-$210.05 M(+3.9%)
Sep 2014
-
-$5.22 M(+8.5%)
-$202.14 M(-16.2%)
Jun 2014
-
-$4.81 M(-97.4%)
-$241.34 M(-0.7%)
Mar 2014
-
-$182.76 M(+1853.8%)
-$242.97 M(+257.9%)
Dec 2013
-$67.89 M(+69.3%)
-$9.35 M(-78.9%)
-$67.89 M(-5.0%)
Sep 2013
-
-$44.42 M(+589.3%)
-$71.44 M(+92.8%)
Jun 2013
-
-$6.44 M(-16.1%)
-$37.05 M(-5.5%)
Mar 2013
-
-$7.68 M(-40.5%)
-$39.20 M(-2.3%)
Dec 2012
-$40.11 M(-25.7%)
-$12.90 M(+28.7%)
-$40.11 M(-11.9%)
Sep 2012
-
-$10.02 M(+16.6%)
-$45.55 M(-11.3%)
Jun 2012
-
-$8.59 M(-0.1%)
-$51.34 M(+3.0%)
Mar 2012
-
-$8.60 M(-53.1%)
-$49.82 M(-7.7%)
Dec 2011
-$53.96 M(+130.1%)
-$18.34 M(+16.0%)
-$53.96 M(+19.8%)
Sep 2011
-
-$15.81 M(+123.5%)
-$45.04 M(+30.0%)
Jun 2011
-
-$7.07 M(-44.5%)
-$34.64 M(+11.1%)
Mar 2011
-
-$12.74 M(+35.3%)
-$31.17 M(+32.9%)
Dec 2010
-$23.46 M(-29.5%)
-$9.41 M(+74.0%)
-$23.46 M(-28.8%)
Sep 2010
-
-$5.41 M(+50.3%)
-$32.95 M(+0.4%)
Jun 2010
-
-$3.60 M(-28.4%)
-$32.82 M(-2.2%)
Mar 2010
-
-$5.03 M(-73.4%)
-$33.56 M(+0.8%)
Dec 2009
-$33.29 M(+8.0%)
-$18.91 M(+258.0%)
-$33.29 M(+77.8%)
Sep 2009
-
-$5.28 M(+21.7%)
-$18.73 M(+7.8%)
Jun 2009
-
-$4.34 M(-8.7%)
-$17.36 M(-30.9%)
Mar 2009
-
-$4.75 M(+9.3%)
-$25.14 M(-18.4%)
Dec 2008
-$30.81 M(-29.9%)
-$4.35 M(+10.9%)
-$30.81 M(+5.4%)
Sep 2008
-
-$3.92 M(-67.6%)
-$29.24 M(-25.4%)
Jun 2008
-
-$12.11 M(+16.1%)
-$39.17 M(+3.3%)
Mar 2008
-
-$10.43 M(+276.3%)
-$37.91 M(-13.8%)
Dec 2007
-$43.97 M(+6.1%)
-$2.77 M(-80.0%)
-$43.97 M(+6.7%)
Sep 2007
-
-$13.85 M(+27.7%)
-$41.20 M(+50.7%)
Jun 2007
-
-$10.85 M(-34.2%)
-$27.34 M(+65.8%)
Mar 2007
-
-$16.49 M
-$16.49 M
Dec 2006
-$41.45 M(+484.5%)
-
-
Dec 2005
-$7.09 M(-61.0%)
-
-
Dec 2004
-$18.18 M
-
-

FAQ

  • What is Emergent BioSolutions annual cash flow from investing activities?
  • What is the all time high annual CFI for Emergent BioSolutions?
  • What is Emergent BioSolutions annual CFI year-on-year change?
  • What is Emergent BioSolutions quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Emergent BioSolutions?
  • What is Emergent BioSolutions quarterly CFI year-on-year change?
  • What is Emergent BioSolutions TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Emergent BioSolutions?
  • What is Emergent BioSolutions TTM CFI year-on-year change?

What is Emergent BioSolutions annual cash flow from investing activities?

The current annual CFI of EBS is $125.20 M

What is the all time high annual CFI for Emergent BioSolutions?

Emergent BioSolutions all-time high annual cash flow from investing activities is $212.30 M

What is Emergent BioSolutions annual CFI year-on-year change?

Over the past year, EBS annual cash flow from investing activities has changed by -$87.10 M (-41.03%)

What is Emergent BioSolutions quarterly cash flow from investing activities?

The current quarterly CFI of EBS is $28.60 M

What is the all time high quarterly CFI for Emergent BioSolutions?

Emergent BioSolutions all-time high quarterly cash flow from investing activities is $257.70 M

What is Emergent BioSolutions quarterly CFI year-on-year change?

Over the past year, EBS quarterly cash flow from investing activities has changed by -$83.40 M (-74.46%)

What is Emergent BioSolutions TTM cash flow from investing activities?

The current TTM CFI of EBS is $125.20 M

What is the all time high TTM CFI for Emergent BioSolutions?

Emergent BioSolutions all-time high TTM cash flow from investing activities is $216.60 M

What is Emergent BioSolutions TTM CFI year-on-year change?

Over the past year, EBS TTM cash flow from investing activities has changed by +$40.00 M (+46.95%)